Abstract

Background and Objectives: The clinical manifestations and course of chronic pancreatitis (CP) are often nonspecific and variable, hampering diagnosis of the risk of exocrine pancreatic insufficiency (EPI). Development of new, reproducible, and non-invasive methods to diagnose EPI is therefore a major priority. The objective of this metabolomic study was to identify novel biomarkers associated with EPI. Materials and Methods: We analyzed 53 samples from patients with CP, 32 with and 21 without EPI, using an untargeted metabolomics workflow based on hydrophilic interaction chromatography coupled to high-resolution mass spectrometry. Principal component and partial least squares-discriminant analyses showed significant between-group differentiation, and univariate and multivariate analyses identified potential candidate metabolites that significantly differed between samples from CP patients with EPI and those without EPI. Results: Excellent results were obtained using a six-metabolic panel to diagnose the presence of EPI in CP patients (area under the ROC curve = 0.785). Conclusions: This study confirms the usefulness of metabolomics in this disease setting, allowing the identification of novel biomarkers to differentiate between the presence and absence of EPI in CP patients.

Highlights

  • Chronic pancreatitis (CP) is a progressive inflammatory disease characterized by irreversible morphological changes of the pancreatic gland, by fibrosis, and by impairment of exocrine and endocrine functions [1]

  • exocrine pancreatic insufficiency (EPI) was diagnosed or ruled out in chronic pancreatitis (CP) patients using the FE-1 test: 60.4% of patients with CP patients were diagnosed with EPI (FE-1 < 200 μg/g) and the remaining 39.6% were not (NO-EPI)

  • Among those diagnosed with EPI, 87.5% had severe EPI (FE-1 < 100 μg/g)

Read more

Summary

Introduction

Chronic pancreatitis (CP) is a progressive inflammatory disease characterized by irreversible morphological changes of the pancreatic gland, by fibrosis, and by impairment of exocrine and endocrine functions [1]. The clinical manifestations and course of chronic pancreatitis (CP) are often nonspecific and variable, hampering diagnosis of the risk of exocrine pancreatic insufficiency (EPI). Development of new, reproducible, and non-invasive methods to diagnose EPI is a major priority. The objective of this metabolomic study was to identify novel biomarkers associated with EPI. Materials and Methods: We analyzed 53 samples from patients with CP, 32 with and 21 without EPI, using an untargeted metabolomics workflow based on hydrophilic interaction chromatography coupled to high-resolution mass spectrometry. Conclusions: This study confirms the usefulness of metabolomics in this disease setting, allowing the identification of novel biomarkers to differentiate between the presence and absence of EPI in CP patients

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call